Autologous transplantation using interleukin 2 activated peripheral blood stem cell graft in chronical myeloid leukemia patients;Autologni transplantace s podanim interleukinem 2 aktivovaneho stepu perifernich kmenovych buniek nemocnym s chronickou myeloidni leukemii

Klinicka Onkologie

Volumn 13, Issue 5, 2000, Pages 159-166

  Hajek, R ^a   Zackova, D ^a   Penka, M ^a   Krahulcova, E ^a   Koristek, Z ^a   Vinklarkova, J ^a   Adler, J ^a   Janovska, E ^a   Indrak, K ^a   Faber, E ^a   Doubek, M ^a   Klabusay, M ^a   Oltova, A ^a   Kuglik, P ^a   Dvorakova, D ^a   Bourkova, L ^a   Dusek, L ^a   Mareschova, I ^a   Mayer, J ^a   Vorlicek, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

CML; IL 2; Immunotherapy; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYTARABINE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; CYTOTOXICITY; HUMAN; IMMUNOTHERAPY; NATURAL KILLER CELL; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL;

EID: 0033745282     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Chronic myeloid leukaemia: A therapeutic challange
2. Allogeneic bone marrow transplantation for CML: A report from the international bone marrow transplant registry
3. Bone marrow transplantation for chronic myeloid leukemi (CML) from unrelated donors and sibling donors: Single center experience
4. Alogenni transplantace perifernich kmenovych krvetvornych bunek po nemyeloabla-tivnim rezimu
5. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups
6. Autologous transplantation therapy for chronic myelogenous leukemia
7. Autologni transplantace kostni drene u nemocnych s chronickou myeloidni leukemii
8. Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study
9. Graft vs. leukaemia reactions in chronic myeloid leukaemia
10. Close simulation of acute graft-versus host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy
11. Interleukin-2+-lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia: A preliminary report
12. Potential of autologous immunologic effector cell for bone marrow purging in patients with chronic myeloid leukemia
13. Helper and cytotoxic lymphocyte responses to chronic myeloid leukemia: Impications for adoptive immunotherapy with T cells
14. Specific human cellular immunity to bcr-abl oncogene-derived peptides
15. CML patient in hematologic remission can mount a cytotoxic T cell response in vitro against the natural peptides eluted from his CML cells
16. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity
17. Experimental evidence of interleukin-2 activity in bone marrow transplantation
18. Minimal residual disease for bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: A review of recent results
19. A pilot study evaluating interleukin-2 activated hematopoetic stem cell transplantation for hematologic malignancies
20. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression
21. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin - 2
22. Chemotherapy of chronic myelocytic leukemia
23. Graft-versus-leukemia reactions after bone marrow transplantation
24. Characteristics od accelerated disease in chronic myelogenous leukaemia
25. Long-term follow-up results of -interferon therapy in chronic myelogenous leukemia at MD Anderson Cancer Center
26. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia
27. Prospective randomized trial of high-dose interleukin-2 alone or in conduction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
28. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
29. Effect of 24-hour culture with interleukin 2 (IL-2) on progenitor cells in autologous bone marrow (ABM) anad peripheral blood stem cells (PBSC) from patients with hematological malignancies
30. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin-2 patients with acute lymphoblastic leukemia
31. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration
32. Immunotherapy of hematological malignancies with autologous bone marrow transplant (AMBT) using in vitro interleukin 2 (IL-2) treated bone marrow (BM)
33. GM-CSF enhances IL-2-activated natural killer lysis of clonogenic AML cells by upregulation target cell expression of ICAM-1
34. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia
35. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from marrow of most early chronic phase but not accelerated-phase chronic myelogenous leukemia patients
36. Genetic marking shows that Ph positive cells present in autologous transplant of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CMI
37. Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells
38. Interleukin 2 activation of human bone marrow in long-term cultures: An effective strategy for purging and generation of of anti-tumor cytotoxic effectors
39. Comparative analysis of autografting in chronic myelogenous leukemia: Effects of priming regimen and marrow or blood origin of stem cells